ecabet
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
1
Earliest trial started Apr 1, 2005 (NCT00198536)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Helicobacter pyloriINHIBITOR
Helicobacter pylori inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1cc2c(cc1S(=O)(=O)O)[C@@]1(C)CCC[C@@](C)(C(=O)O)[C@@H]1CC2- Mol. weight
- 380.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2104585 ↗
Also known as
- 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt
- 12-sulfodehydroabietic acid
- ecabet
- ecabet
- ecabet
- ecabet
- ecabet
- ecabet
- ecabet
- ecabet
- ecabet sodium
- ecabet sodium
- ecabet sodium
- ecabet sodium
- ecabet sodium
- ta 2711
- ta-2711
- ta-2711
- ta-2711
- ta-2711
- ta-2711
- ta-2711
- ta-2711e
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01308177 | Phase 4 | Mar 1, 2011 | Sungkyunkwan University |
| NCT01039558 | N/A | Dec 1, 2009 | Seoul National University |
| NCT00667004 | Phase 2 | Apr 1, 2008 | Bausch & Lomb, ISTA Pharmaceuticals |
| NCT00370747 | Phase 2 | Sep 1, 2006 | Bausch & Lomb, ISTA Pharmaceuticals |
| NCT00198536 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2005 | Bausch & Lomb, ISTA Pharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bausch & Lomb | For profit | 3 | 3 | 2 | 2005 |
| ISTA Pharmaceuticals | For profit | 3 | 0 | 2 | 2005 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Sungkyunkwan University | Academic/Hospital | 1 | 1 | 1 | 2011 |
4 organizations
Page 1 / 1